Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): Antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer

J. C. Yang, S. L. Schwarz, D. M. Perry-Lalley, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

A polyethylene glycol-modified form of recombinant human IL-2 (PEG-IL-2) was tested for murine antitumor effects in vitro and in vivo. This PEG-IL-2 was demonstrated to retain the in vitro ability to support T cell proliferation, enhance a mixed lymphocyte reaction, and generate lymphokine- activated killer (LAK) cells. It was found to have a circulating half-life in mice 25 times longer than unmodified recombinant IL-2 (RIL-2). Serum levels were detected up to 60 h after a single intravenous injection. When given as a single, intravenous administration the antitumor effect of this material was similar to multiple, repeated bolus doses of RIL-2. PEG-IL-2 was also found to support the in vivo efficacy of adoptively transferred LAK cells and tumor infiltrating lymphocytes (TIL). Using a congenic TIL (Thy 1.1), persistence of adoptively transferred TIL was found to be prolonged with PEG- IL-2 compared to repeated boluses of RIL-2. Four days after transfer, twice as many Thy 1.1 TIL were recoverable from the lungs of mice given PEG-IL-2. These studies show that PEG-IL-2 is a modified lymphokine with significant antitumor activity in murine systems and is superior to bolus RIL-2 in enhancing the survival of adoptively transferred TIL.

Original languageEnglish (US)
Pages (from-to)475-480
Number of pages6
JournalLymphokine and Cytokine Research
Volume10
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Adoptive Transfer
Interleukin-2
Tumor-Infiltrating Lymphocytes
Lymphokine-Activated Killer Cells
polyethylene glycol-modified interleukin-2
Mixed Lymphocyte Culture Test
Lymphokines
Intravenous Injections
Intravenous Administration
Half-Life
Cell Proliferation
T-Lymphocytes
Lung
Survival

ASJC Scopus subject areas

  • Immunology
  • Hematology

Cite this

Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2) : Antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer. / Yang, J. C.; Schwarz, S. L.; Perry-Lalley, D. M.; Rosenberg, S. A.

In: Lymphokine and Cytokine Research, Vol. 10, No. 6, 1991, p. 475-480.

Research output: Contribution to journalArticle

@article{4717743ac6714c098331e58735a60927,
title = "Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): Antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer",
abstract = "A polyethylene glycol-modified form of recombinant human IL-2 (PEG-IL-2) was tested for murine antitumor effects in vitro and in vivo. This PEG-IL-2 was demonstrated to retain the in vitro ability to support T cell proliferation, enhance a mixed lymphocyte reaction, and generate lymphokine- activated killer (LAK) cells. It was found to have a circulating half-life in mice 25 times longer than unmodified recombinant IL-2 (RIL-2). Serum levels were detected up to 60 h after a single intravenous injection. When given as a single, intravenous administration the antitumor effect of this material was similar to multiple, repeated bolus doses of RIL-2. PEG-IL-2 was also found to support the in vivo efficacy of adoptively transferred LAK cells and tumor infiltrating lymphocytes (TIL). Using a congenic TIL (Thy 1.1), persistence of adoptively transferred TIL was found to be prolonged with PEG- IL-2 compared to repeated boluses of RIL-2. Four days after transfer, twice as many Thy 1.1 TIL were recoverable from the lungs of mice given PEG-IL-2. These studies show that PEG-IL-2 is a modified lymphokine with significant antitumor activity in murine systems and is superior to bolus RIL-2 in enhancing the survival of adoptively transferred TIL.",
author = "Yang, {J. C.} and Schwarz, {S. L.} and Perry-Lalley, {D. M.} and Rosenberg, {S. A.}",
year = "1991",
language = "English (US)",
volume = "10",
pages = "475--480",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2)

T2 - Antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer

AU - Yang, J. C.

AU - Schwarz, S. L.

AU - Perry-Lalley, D. M.

AU - Rosenberg, S. A.

PY - 1991

Y1 - 1991

N2 - A polyethylene glycol-modified form of recombinant human IL-2 (PEG-IL-2) was tested for murine antitumor effects in vitro and in vivo. This PEG-IL-2 was demonstrated to retain the in vitro ability to support T cell proliferation, enhance a mixed lymphocyte reaction, and generate lymphokine- activated killer (LAK) cells. It was found to have a circulating half-life in mice 25 times longer than unmodified recombinant IL-2 (RIL-2). Serum levels were detected up to 60 h after a single intravenous injection. When given as a single, intravenous administration the antitumor effect of this material was similar to multiple, repeated bolus doses of RIL-2. PEG-IL-2 was also found to support the in vivo efficacy of adoptively transferred LAK cells and tumor infiltrating lymphocytes (TIL). Using a congenic TIL (Thy 1.1), persistence of adoptively transferred TIL was found to be prolonged with PEG- IL-2 compared to repeated boluses of RIL-2. Four days after transfer, twice as many Thy 1.1 TIL were recoverable from the lungs of mice given PEG-IL-2. These studies show that PEG-IL-2 is a modified lymphokine with significant antitumor activity in murine systems and is superior to bolus RIL-2 in enhancing the survival of adoptively transferred TIL.

AB - A polyethylene glycol-modified form of recombinant human IL-2 (PEG-IL-2) was tested for murine antitumor effects in vitro and in vivo. This PEG-IL-2 was demonstrated to retain the in vitro ability to support T cell proliferation, enhance a mixed lymphocyte reaction, and generate lymphokine- activated killer (LAK) cells. It was found to have a circulating half-life in mice 25 times longer than unmodified recombinant IL-2 (RIL-2). Serum levels were detected up to 60 h after a single intravenous injection. When given as a single, intravenous administration the antitumor effect of this material was similar to multiple, repeated bolus doses of RIL-2. PEG-IL-2 was also found to support the in vivo efficacy of adoptively transferred LAK cells and tumor infiltrating lymphocytes (TIL). Using a congenic TIL (Thy 1.1), persistence of adoptively transferred TIL was found to be prolonged with PEG- IL-2 compared to repeated boluses of RIL-2. Four days after transfer, twice as many Thy 1.1 TIL were recoverable from the lungs of mice given PEG-IL-2. These studies show that PEG-IL-2 is a modified lymphokine with significant antitumor activity in murine systems and is superior to bolus RIL-2 in enhancing the survival of adoptively transferred TIL.

UR - http://www.scopus.com/inward/record.url?scp=0026322123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026322123&partnerID=8YFLogxK

M3 - Article

C2 - 1804310

AN - SCOPUS:0026322123

VL - 10

SP - 475

EP - 480

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 6

ER -